{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:28:50Z","timestamp":1776817730262,"version":"3.51.2"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"11","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2025-0332_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Continuous glucose monitors (CGM) are the mainstay of glucose monitoring in type 1 diabetes (T1D). However, the impact of race\/ethnicity and the timing of CGM adoption following T1D diagnosis is unclear. We examined the effect of race\/ethnicity and CGM adoption on glycemia and partial remission (PR) in\u00a0T1D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0332_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A 24-month longitudinal retrospective cohort study of youth with T1D who used Dexcom CGM G5\/G6 between 2018 and 2022 was conducted. Subjects were classified as non-Hispanic White (NHW) or Other (Asian, Black\/African American, Hispanic\/Latino, or other). Glycemia was measured as %change in hemoglobin A\n                      <jats:sub>1c<\/jats:sub>\n                      (A\n                      <jats:sub>1c<\/jats:sub>\n                      ) and time in range (TIR) from baseline to 24\u00a0months. PR was denoted as an insulin-dose-adjusted A\n                      <jats:sub>1c<\/jats:sub>\n                      (IDAA\n                      <jats:sub>1c<\/jats:sub>\n                      ) value of\u00a0\u22649. The statistical approach included the paired t-test, the Wilcoxon signed-rank test, and mixed effects models for repeated measures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0332_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Early CGM adoption occurred in 90\u202f% (61\/68) of NHW subjects vs. 63\u202f% (43\/68) of the Other, p=0.0003. Early CGM adoption was associated with improved glycemia and PR as marked by a significantly greater %decrease in A\n                      <jats:sub>1c<\/jats:sub>\n                      , p=0.0008, and IDAA1c, p=0.0003, at 24\u00a0months following CGM adoption. Temporal trends in A1c and IDAA1c were significantly lower among NHW subjects, p&lt;0.0001, and the probability of PR was significantly greater, p&lt;0.0001. Early CGM adoption conferred a greater probability of PR than late CGM adoption, p&lt;0.0001.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0332_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early adoption of diabetes technology should be accelerated in all children with T1D, particularly minority children, to reduce hyperglycemia, promote PR, and close the gap in diabetes care and complications in the United\u00a0States.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2025-0332","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:54:22Z","timestamp":1758236062000},"page":"1135-1143","source":"Crossref","is-referenced-by-count":1,"title":["Impact of race and delayed adoption of diabetes technology on glycemia and partial remission in type 1 diabetes"],"prefix":"10.1515","volume":"38","author":[{"given":"Adriana","family":"Chader-Gata Garcia","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics , Cohen Children\u2019s Medical Center , New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komalpreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics , Cohen Children\u2019s Medical Center , New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashida","family":"Talib","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics , Cohen Children\u2019s Medical Center , New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parissa","family":"Salemi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics , Cohen Children\u2019s Medical Center , New York , USA"},{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Fishbein","sequence":"additional","affiliation":[{"name":"Biostatistics Unit , Office of Academic Affairs , New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin Udoka","family":"Nwosu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics , Cohen Children\u2019s Medical Center , New York , USA"},{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"2025103018011141899_j_jpem-2025-0332_ref_001","doi-asserted-by":"crossref","unstructured":"Addala, A, Hanes, S, Naranjo, D, Maahs, DM, Hood, KK. Provider implicit bias impacts pediatric type 1 diabetes technology recommendations in the United\u00a0States: findings from the gatekeeper study. J\u00a0Diabetes Sci Technol 2021;15:1027\u201333. https:\/\/doi.org\/10.1177\/19322968211006476.","DOI":"10.1177\/19322968211006476"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_002","doi-asserted-by":"crossref","unstructured":"Willi, SM, Miller, KM, DiMeglio, LA, Klingensmith, GJ, Simmons, JH, Tamborlane, WV, et al.. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. Pediatrics 2015;135:424\u201334. https:\/\/doi.org\/10.1542\/peds.2014-1774.","DOI":"10.1542\/peds.2014-1774"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_003","doi-asserted-by":"crossref","unstructured":"Agarwal, S, Schechter, C, Gonzalez, J, Long, JA. Racial-ethnic disparities in diabetes technology use among young adults with type 1 diabetes. Diabetes Technol Ther 2021;23:306\u201313. https:\/\/doi.org\/10.1089\/dia.2020.0338.","DOI":"10.1089\/dia.2020.0338"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_004","unstructured":"National diabetes statistics report. 2024. [Internet] [cited January 15, 2025]. Available from: https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html."},{"key":"2025103018011141899_j_jpem-2025-0332_ref_005","doi-asserted-by":"crossref","unstructured":"Foster, NC, Beck, RW, Miller, KM, Clements, MA, Rickels, MR, DiMeglio, LA, et al.. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther 2019;21:66\u201372. https:\/\/doi.org\/10.1089\/dia.2018.0384.","DOI":"10.1089\/dia.2018.0384"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_006","doi-asserted-by":"crossref","unstructured":"Miller, KM, Beck, RW, Foster, NC, Maahs, DM. HbA1c levels in type 1 diabetes from early childhood to older adults: a deeper dive into the influence of technology and socioeconomic status on HbA1c in the T1D exchange clinic registry findings. Diabetes Technol Ther 2020;22:645\u201350. https:\/\/doi.org\/10.1089\/dia.2019.0393.","DOI":"10.1089\/dia.2019.0393"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_007","doi-asserted-by":"crossref","unstructured":"Nwosu, BU, Yeasmin, S, Ayyoub, S, Rupendu, S, Villalobos-Ortiz, TR, Jasmin, G, et al.. Continuous glucose monitoring reduces pubertal hyperglycemia of type 1 diabetes. J\u00a0Pediatr Endocrinol Metab 2020;33:865\u201372. https:\/\/doi.org\/10.1515\/jpem-2020-0057.","DOI":"10.1515\/jpem-2020-0057"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_008","doi-asserted-by":"crossref","unstructured":"Chico, A, Moreno-Fernandez, J, Fernandez-Garcia, D, Sola, E. The hybrid closed-loop system tandem t:slim X2 with control-IQ technology: expert recommendations for better management and optimization. Diabetes Therapy: Res Treat Educ Diabetes Relat Disord 2024;15:281\u201395. https:\/\/doi.org\/10.1007\/s13300-023-01486-2.","DOI":"10.1007\/s13300-023-01486-2"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_009","doi-asserted-by":"crossref","unstructured":"Tanenbaum, ML, Zaharieva, DP, Addala, A, Ngo, J, Prahalad, P, Leverenz, B, et al.. \u2018I was ready for it at the beginning\u2019: parent experiences with early introduction of continuous glucose monitoring following their child\u2019s type 1 diabetes diagnosis. Diabet Med 2021;38:e14567. https:\/\/doi.org\/10.1111\/dme.14567.","DOI":"10.1111\/dme.14567"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_010","doi-asserted-by":"crossref","unstructured":"McVean, J, Forlenza, GP, Beck, RW, Bauza, C, Bailey, R, Buckingham, B, et al.. Effect of tight glycemic control on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. JAMA 2023;329:980\u20139. https:\/\/doi.org\/10.1001\/jama.2023.2063.","DOI":"10.1001\/jama.2023.9113"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_011","doi-asserted-by":"crossref","unstructured":"Steffes, MW, Sibley, S, Jackson, M, Thomas, W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832\u20136. https:\/\/doi.org\/10.2337\/diacare.26.3.832.","DOI":"10.2337\/diacare.26.3.832"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_012","doi-asserted-by":"crossref","unstructured":"Fureman, AL, Bladh, M, Carlsson, A, Forsander, G, Lilja, M, Ludvigsson, J, et al.. Partial clinical remission of type 1 diabetes in Swedish children \u2013 a longitudinal study from the Swedish national quality register (SWEDIABKIDS) and the better diabetes diagnosis (BDD) study. Diabetes Technol Therapeut 2024;26:851\u201361. https:\/\/doi.org\/10.1089\/dia.2024.0112.","DOI":"10.1089\/dia.2024.0112"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_013","doi-asserted-by":"crossref","unstructured":"Nwosu, BU, Parajuli, S, Sharma, RB, Lee, AF. Effect of ergocalciferol on \u03b2-cell function in new-onset type 1 diabetes: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2024;7:e241155. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.1155.","DOI":"10.1001\/jamanetworkopen.2024.1155"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_014","doi-asserted-by":"crossref","unstructured":"Taylor, PN, Collins, KS, Lam, A, Karpen, SR, Greeno, B, Walker, F, et al.. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis. Lancet Diabetes Endocrinol 2023;11:915\u201325. https:\/\/doi.org\/10.1016\/s2213-8587-23-00267-x.","DOI":"10.1016\/S2213-8587(23)00267-X"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_015","doi-asserted-by":"crossref","unstructured":"Gr\u00f6nberg, A, Espes, D, Carlsson, PO. Better HbA1c during the first years after diagnosis of type 1 diabetes is associated with residual C peptide 10\u00a0years later. BMJ Open Diabetes Res Care 2020;8. https:\/\/doi.org\/10.1136\/bmjdrc-2019-000819.","DOI":"10.1136\/bmjdrc-2019-000819"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_016","doi-asserted-by":"crossref","unstructured":"McVean, J, Forlenza, GP, Beck, RW, Bauza, C, Bailey, R, Buckingham, B, et al.. Effect of tight glycemic control on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. JAMA 2023;329:980\u20139. https:\/\/doi.org\/10.1001\/jama.2023.2063.","DOI":"10.1001\/jama.2023.9113"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_017","doi-asserted-by":"crossref","unstructured":"Narendran, P, Tomlinson, C, Beese, S, Sharma, P, Harris, I, Adriano, A, et al.. A systematic review and meta-analysis of interventions to preserve insulin-secreting beta-cell function in people newly diagnosed with type 1 diabetes: results from intervention studies aimed at improving glucose control. Diabet Med 2022;39:e14730. https:\/\/doi.org\/10.1111\/dme.14730.","DOI":"10.1111\/dme.14730"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_018","doi-asserted-by":"crossref","unstructured":"Enander, R, Adolfsson, P, Bergdahl, T, Forsander, G, Ludvigsson, J, Hanas, R. Beta cell function after intensive subcutaneous insulin therapy or intravenous insulin infusion at onset of type 1 diabetes in children without ketoacidosis. Pediatr Diabetes 2018;19:1079\u201385. https:\/\/doi.org\/10.1111\/pedi.12657.","DOI":"10.1111\/pedi.12657"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_020","doi-asserted-by":"crossref","unstructured":"Conway, RB, Gerard Gonzalez, A, Shah, VN, Geno Rasmussen, C, Akturk, HK, Pyle, L, et al.. Racial disparities in diabetes technology adoption and their association with HbA1c and diabetic ketoacidosis. Diabetes Metab Syndr Obes 2023;16:2295\u2013310. https:\/\/doi.org\/10.2147\/dmso.s416192.","DOI":"10.2147\/DMSO.S416192"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_021","doi-asserted-by":"crossref","unstructured":"Buscemi, J, Saiyed, N, Silva, A, Ghahramani, F, Benjamins, MR. Diabetes mortality across the 30 biggest U.S. cities: assessing overall trends and racial inequities. Diabetes Res Clin Pract 2021;173:108652. https:\/\/doi.org\/10.1016\/j.diabres.2021.108652.","DOI":"10.1016\/j.diabres.2021.108652"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_022","doi-asserted-by":"crossref","unstructured":"Addala, A, Auzanneau, M, Miller, K, Maier, W, Foster, N, Kapellen, T, et al.. A decade of disparities in diabetes technology use and HbA1c in pediatric type 1 diabetes: a transatlantic comparison. Diabetes Care 2021;44:133\u201340. https:\/\/doi.org\/10.2337\/dc20-0257.","DOI":"10.2337\/dc20-0257"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_023","doi-asserted-by":"crossref","unstructured":"Nwosu, BU, Pellizzari, M, Pavlovic, MN, Ciron, J, Talib, R, Sohail, R. Virtual insulin pump initiation is safe effective in children adolescents with type 1 diabetes. Front Clin Diabetes Healthc 2024;5:1362627. https:\/\/doi.org\/10.3389\/fcdhc.2024.1362627.","DOI":"10.3389\/fcdhc.2024.1362627"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_024","doi-asserted-by":"crossref","unstructured":"Mortensen, HB, Hougaard, P, Swift, P, Hansen, L, Holl, RW, Hoey, H, et al.. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 2009;32:1384\u201390. https:\/\/doi.org\/10.2337\/dc08-1987.","DOI":"10.2337\/dc08-1987"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_025","doi-asserted-by":"crossref","unstructured":"Nwosu, BU, Zhang, B, Ayyoub, SS, Choi, S, Villalobos-Ortiz, TR, Alonso, LC, et al.. Children with type 1 diabetes who experienced a honeymoon phase had significantly lower LDL cholesterol 5\u00a0years after diagnosis. PLoS One 2018;13:e0196912. https:\/\/doi.org\/10.1371\/journal.pone.0196912.","DOI":"10.1371\/journal.pone.0196912"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_026","doi-asserted-by":"crossref","unstructured":"Nwosu, BU, Al-Halbouni, L, Parajuli, S, Jasmin, G, Zitek-Morrison, E, Barton, BA. COVID-19 pandemic and pediatric type 1 diabetes: No significant change in glycemic control during the pandemic lockdown of 2020. Front Endocrinol (Lausanne) 2021;12:703905. https:\/\/doi.org\/10.3389\/fendo.2021.703905.","DOI":"10.3389\/fendo.2021.703905"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_027","doi-asserted-by":"crossref","unstructured":"Conway, RB, Snell-Bergeon, J, Honda-Kohmo, K, Peddi, AK, Isa, SB, Sulong, S, et al.. Disparities in diabetes technology uptake in youth and young adults with type 1 diabetes: a global perspective. J\u00a0Endocr Soc 2024;9:bvae210. https:\/\/doi.org\/10.1210\/jendso\/bvae210.","DOI":"10.1210\/jendso\/bvae210"},{"key":"2025103018011141899_j_jpem-2025-0332_ref_028","doi-asserted-by":"crossref","unstructured":"Berg, AK, Passanisi, S, von dem Berge, T, Chobot, A, Elbarbary, NS, Pelicand, J, et al.. SKIN-PEDIC: a worldwide assessment of skin problems in children and adolescents using diabetes devices. Horm Res Paediatr 2025:1\u201314. https:\/\/doi.org\/10.1159\/000545428.","DOI":"10.1159\/000545428"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0332\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0332\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:02:06Z","timestamp":1761847326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0332\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,21]]},"published-print":{"date-parts":[[2025,11,25]]}},"alternative-id":["10.1515\/jpem-2025-0332"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2025-0332","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}